GlassScriptPhysician profile
Michelle Tharp
NPI 1720528011
$27,529.73
in general payments reported to CMS, 2019-2025
14 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $51.05 · 2024: $5,364 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $6,878 · Travel and Lodging: $6,554 · Food and Beverage: $1,683 · Honoraria: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,715.00 |
| Consulting Fee | $6,877.50 |
| Travel and Lodging | $6,554.14 |
| Food and Beverage | $1,683.14 |
| Honoraria | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $19,019.31 | 2022-2025 | Palynziq, Kuvan |
| Genzyme Corporation | $5,176.71 | 2023-2025 | |
| Ptc Therapeutics, INC. | $1,441.39 | 2025 | Sephience |
| Chiesi USA, INC. | $1,359.93 | 2024-2025 | Elfabrio, Lamzede |
| Abbvie INC. | $124.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.48 | 2024-2025 | Elaprase, Vpriv |
| Ultragenyx Pharmaceutical INC. | $69.31 | 2023-2025 | Dojolvi |
| Cycle Pharmaceuticals INC | $62.05 | 2024-2025 | Javygtor |
| Orchard Therapeutics North America | $44.09 | 2025 | Lenmeldy |
| Zevra Therapeutics INC | $43.05 | 2025 | Olpruva |
| Mirum Pharmaceuticals, INC. | $23.63 | 2024 | Cholbam |
| Amicus Therapeutics, INC. | $23.01 | 2024 | Galafold |
| Recordati_rare_diseases_inc. | $19.26 | 2023 | Carbaglu, Cystadane |
| Intrabio INC | $14.56 | 2025 | Aqneursa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Tharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.